InvestorsHub Logo

zerosnoop

05/17/22 11:57 PM

#52291 RE: mr_sano #52290

NOT TRUE. QS doesn't need to use toxic debt as shareholders & directors have financed operations. That's the FACTS in the public filings.

UPDATED. More "INSIDER BUYING". Below is a recap of all the RECENT "INSIDER BUYING" by QS directors. This includes the RECENT $275,000 investment by the uncompensated ceo Kyte. The list CONTINUES to grow & grow

https://ir.qsenergy.com/all-sec-filings/content/0001683168-21-003139/ownership.html

https://ir.qsenergy.com/all-sec-filings/content/0001683168-21-003137/ownership.html

https://ir.qsenergy.com/all-sec-filings/content/0001683168-20-002014/ownership.html

https://ir.qsenergy.com/all-sec-filings/content/0001683168-20-002016/ownership.html


(1) On 8/5/2016 Don Dickson invests $70,000 in a Private Placement offering of convertible notes and warrants.

(2) On 10/13/2016 Don Dickson converts his note into common stock.

(3) On 4/17/2017 Dr. Eric Bunting invests $50,000 in a Private Placement offering of convertible notes and warrants.

(4) On 5/15/17 Richard Munn invests $10,000 in a Private Placement offering of convertible notes and warrants. He immediately converts the notes to common stock.

(5) On 5/15/2017 Richard Munn buys 42,000 shares of common stock in the open market at $0.24 per share.

(6) On 5/31/2017 Thomas Bundros invests $100,000 in a private Placement of convertible notes and warrants. He immediately converts the notes to common stock.

(7) On 7/19/2017 Dr. Eric Bunting invests an additional $40,000 to convert his warrants and stock options into common stock well before their expiration dates.

(8) On 7/30/2017 Don Dickson invests an additional $38,500 to convert warrants into common stock.

(9) On 8/2/2017 Gary Buchler invests $50,000 to buy common stock at market prices and convert all of his vested stock options.

(10) On 10/2/2017 Dr. Eric Bunting invests an additional $33,875 to buy 125,000 shares of common stock in the open market at $.271 per share. He also converts 178,002 of his newly vested stock options into common stock at an out of pocket cost of $12,460. This brings his total common stock holdings to 6,735,430 shares worth approx. $1.8 million at today's price.

(11) On 2/6/2018 Dr. Eric Bunting converts 179,710 of his newly vested stock options into common stock, well before their expiration date, at an out of pocket cost of $12,580.

(12) On 3/30/2018 Dr. Eric Bunting invests another $40,000 in a private Placement of convertible notes and warrants. He immediately converts the notes to common stock.

(13) On 3/30/2018 Dr. Eric Bunting invests an additional $18,000 to convert warrants into common stock, well before their expiration date.

(14) On 05/14/2018 Richard Munn invests an additional $5,500 to convert his 110,000 warrants into common stock.

(15) On 11/26/2018 Dr Eric Bunting invests another $25,000 in a private Placement of convertible notes and warrants.

(16) On 11/26/2018 Don Dickson invests another $25,000 in a private Placement of convertible notes and warrants.

(17) On 02/21/2019 ceo Jason Lane invests $25,000 in a private Placement of convertible notes and warrants.

(18) On 02/25/2019 Thomas Bundros invests $15,000 in a private Placement of convertible notes and warrants.

(19) On 02/25/2019 Richard Munn invests $10,000 in a private Placement of convertible notes and warrants.

(20) On 3/21/2019 Dr. Eric Bunting invests an additional $50,000 to convert warrants into common stock, well before their expiration date.

(21) On 04/03/2019 Thomas Bundros invests an additional $8,250 to convert warrants into common stock, well before their expiration date.

(22) On 02/25/2019 Richard Munn invests an additional $11,000 to convert warrants into common stock, well before their expiration date.

(23) On 06/04/2019 Dr Eric Bunting invests another $100,000 in a private Placement of convertible notes and warrants.

(24) On 09/23/2019 Dr Eric Bunting invests another $200,000 in a private Placement of convertible notes and warrants.

(25) On 03/23/2020 Dr Eric Bunting invests another $30,000 in a private Placement of convertible notes and warrants.

(26) On 03/18/2020 chairman Jason Lane invests another $20,000 in a private Placement of convertible notes and warrants.

(27) On 06/12/2020 ceo Don Dickson invests another $10,000 in a private placement of convertible notes and warrants.

(28) On 06/19/2020 cfo Michael McMullen invests $6,600 in a private placement of convertible notes and warrants.

(29) On 06/19/2020 Richard Munn invests another $10,000 in a private placement of convertible notes and warrants.

(30) On 06/19/2020 Dr Eric Bunting invests another $30,000 in a private placement of convertible notes and warrants.

(31) During the period August 2020, through June 2021 (the “Relevant Period”), Mr. Kyte provided the Company with $275,000 in working capital. During this Relevant Period, Mr. Kyte also introduced capital to the Company in the sum of $150,000 from third-party sources. This capital was received by the Company in exchange for convertible promissory notes and related warrants. With this additional third-party capital infusion, during this Relevant Period, Mr. Kyte was responsible, directly and indirectly, for providing the Company with working capital in the amount of $425,000.

All of the individuals named above are part of QSEP's Board of Directors.
All of them are investing their own money in QSEP.
While NDA's may prevent them from talking about the specifics of any particular corporate relationships, this is a powerful alternative way to express just how confident they are in QSEP's immediate future.

I've emphasized the word immediate because I think the motivation for early conversion of 10 year stock options is based on a strong belief that the stock will be going substantially higher in the near term. This early conversion will reduce the future tax burden substantially if that were to occur (long term capital gain instead of ordinary income).

The "bargain element" of a stock option is taxed as ordinary income while the remaining gain is taxed at the lower capital gains rate. Exercise of a stock option while the underlying security price is low insures that the "bargain element" will also be low allowing for the best tax outcome (the bargain element is the difference between the price at the time of exercise and the grant price). For the owner of a QSEP stock option it requires a very powerful incentive to give up a 10 year "free look". A savvy investor would hold onto a stock option as long as possible, exercising and putting up money only at a time when the outlook was so positive that it is likely to move the stock substantially higher. Anybody exercising their stock options today must feel now is that time.

zerosnoop

05/17/22 11:59 PM

#52292 RE: mr_sano #52290

GEMS & FACTS from the latest 10k filing :

All collected data at the AOT demonstration site will be normalized such that it can be used to evaluate the financial and operational benefits across a wide range of commercial operating scenarios without disclosing confidential details of our demonstration partner’s operations. We believe that real-world data from our AOT project may be used to accelerate our desire to achieve commercial adoption of our AOT technology, positioning us to re-engage with industry executives.

The results of the electrical testing of the insulating material showed that the material is functioning as designed.

New materials were sourced and tested as potential replacements. A couple of new materials have been found that offer improved stability when submerged in crude oil for extended periods of time.

The data has been shared with our vendors and they are working on providing us with samples of commercial versions of the promising materials.

We have also validated that a new design concept for the grid pack will reduce arcing and allowed us to apply full voltage during a recent test. A 3rd party engineering firm with proper experience and three-dimensional modeling software was engaged. A design review has been completed and final drawings have been received.

The Company continues to optimize and value engineer its AOT product line, targeting both midstream and upstream markets. The Company has installed an AOT demonstration project in cooperation with a major U.S. pipeline operator.

Beginning in the second quarter of 2012, the Company began the design and engineering efforts required to transition from laboratory and prototype testing to AOT units designed for full-scale commercial testing. The Company established its supply chain, designs, drawings, engineering, certifications and specifications to comply with the engineering audit processes as dictated by the energy industry regulation processes and North American regulatory bodies. We have built, delivered and tested, under limited duration and conditions, AOT equipment on a high-volume commercial pipeline.

At December 31, 2021, the Company had cash on hand in the amount of $114,000. Management estimates that the current funds on hand will be sufficient to continue operations through September 2022.

Although, as reported by ATS, the efficacy of the AOT technology operated in the TransCanada field test was constrained due to limitations of the electric field applied by that unit’s power supply, subsequent analysis by QS Energy personnel of ATS test results compared against laboratory tests performed at Temple University on oil samples provided by TransCanada revealed a single test run in which the electric field generated by the AOT was sufficient to fully treat the oil given operating conditions at the time of the test. In this test run, ATS measured a 23% reduction in viscosity three hours after AOT treatment. Laboratory tests at Temple University performed on a sample of crude oil provided by TransCanada of the same type treated in that specific field test measured a 27% reduction in viscosity in the laboratory immediately following treatment. Allowing for the actual three-hour of recovery time of the field test measurement, the resulting field test viscosity reduction of 23% correlates very well to the 27% viscosity reduction achieved in the laboratory setting.

In the fourth quarter 2016, the Company entered a contract to provide these onsite testing services to a North American oil producer and pipeline operator over a one-week period in early 2017 at a fixed price of $50,000. This test was performed in January 2017; data analysis and final report was completed in March 2017. Test results demonstrated viscosity reduction under limited laboratory conditions. The oil producer requested access to observe a full-scale demonstration facility and view operating data when they become available.

We believe QS Energy’s technologies will enable the petroleum industry to gain key value advantages boosting profit, while satisfying the needs of regulatory bodies at the same time. Key players in the pipeline industry continue to demonstrate interest in our technologies.

We believe QS Energy’s AOT technology is strategically aligned with the major requirements and challenges facing the petroleum pipeline economy. The AOT is designed to increase pipeline flowrate while relaxing pipeline viscosity requirements, effectively increasing pipeline capacity and reducing or eliminating bottlenecks. This has the ancillary benefit of reducing the need to add diluent or heat to reduce viscosity while reducing reliance on more costly truck and rail transport to meet increasing capacity demands. Our AOT technology may also mitigate costly operating factors such as vapor pressure, pigging (pipeline cleaning) frequency, power consumption, and onset of turbulent flow. Of these factors, vapor pressure, which may be mitigated by AOT through reduced reliance on diluent and a reduction in heat buildup in transit, is of high importance to many pipeline operators as vapor pressure is tightly controlled by the EPA and is very expensive to mitigate by other means. We are now seeking to commercialize AOT as a cost-efficient solution for both new and existing pipeline operations.